426 related articles for article (PubMed ID: 28611190)
1. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
[TBL] [Abstract][Full Text] [Related]
2. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
[TBL] [Abstract][Full Text] [Related]
3. CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.
Javadi M; Richmond TD; Huang K; Barber DL
J Biol Chem; 2013 Jul; 288(27):19459-70. PubMed ID: 23696637
[TBL] [Abstract][Full Text] [Related]
4. Cbl-mediated K63-linked ubiquitination of JAK2 enhances JAK2 phosphorylation and signal transduction.
Liu CS; Yang-Yen HF; Suen CS; Hwang MJ; Yen JJ
Sci Rep; 2017 Jul; 7(1):4613. PubMed ID: 28676638
[TBL] [Abstract][Full Text] [Related]
5. Lnk constrains myeloproliferative diseases in mice.
Bersenev A; Wu C; Balcerek J; Jing J; Kundu M; Blobel GA; Chikwava KR; Tong W
J Clin Invest; 2010 Jun; 120(6):2058-69. PubMed ID: 20458146
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
Sanada M; Suzuki T; Shih LY; Otsu M; Kato M; Yamazaki S; Tamura A; Honda H; Sakata-Yanagimoto M; Kumano K; Oda H; Yamagata T; Takita J; Gotoh N; Nakazaki K; Kawamata N; Onodera M; Nobuyoshi M; Hayashi Y; Harada H; Kurokawa M; Chiba S; Mori H; Ozawa K; Omine M; Hirai H; Nakauchi H; Koeffler HP; Ogawa S
Nature; 2009 Aug; 460(7257):904-8. PubMed ID: 19620960
[TBL] [Abstract][Full Text] [Related]
7. PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371.
Chen H; Bai Y; Kobayashi M; Xiao S; Cai W; Barajas S; Chen S; Miao J; Meke FN; Vemula S; Ropa JP; Croop JM; Boswell HS; Wan J; Jia Y; Liu H; Li LS; Altman JK; Eklund EA; Ji P; Tong W; Band H; Huang DT; Platanias LC; Zhang ZY; Liu Y
Blood; 2023 Jan; 141(3):244-259. PubMed ID: 36206490
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.
Jiang J; Balcerek J; Rozenova K; Cheng Y; Bersenev A; Wu C; Song Y; Tong W
J Clin Invest; 2012 Jun; 122(6):2079-91. PubMed ID: 22546852
[TBL] [Abstract][Full Text] [Related]
9. Cbl negatively regulates erythropoietin-induced growth and survival signaling through the proteasomal degradation of Src kinase.
Shintani T; Ohara-Waki F; Kitanaka A; Tanaka T; Kubota Y
Blood Cells Mol Dis; 2014 Dec; 53(4):211-8. PubMed ID: 25084697
[TBL] [Abstract][Full Text] [Related]
10. Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.
Nadeau SA; An W; Mohapatra BC; Mushtaq I; Bielecki TA; Luan H; Zutshi N; Ahmad G; Storck MD; Sanada M; Ogawa S; Band V; Band H
J Biol Chem; 2017 Mar; 292(9):3666-3682. PubMed ID: 28082680
[TBL] [Abstract][Full Text] [Related]
11. Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy.
An W; Nadeau SA; Mohapatra BC; Feng D; Zutshi N; Storck MD; Arya P; Talmadge JE; Meza JL; Band V; Band H
Oncotarget; 2015 Apr; 6(12):10498-509. PubMed ID: 25871390
[TBL] [Abstract][Full Text] [Related]
12. Acquired expression of
Nakata Y; Ueda T; Nagamachi A; Yamasaki N; Ikeda KI; Sera Y; Takubo K; Kanai A; Oda H; Sanada M; Ogawa S; Tsuji K; Ebihara Y; Wolff L; Honda ZI; Suda T; Inaba T; Honda H
Blood; 2017 Apr; 129(15):2148-2160. PubMed ID: 28209720
[TBL] [Abstract][Full Text] [Related]
13. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Koren-Michowitz M; Gery S; Tabayashi T; Lin D; Alvarez R; Nagler A; Koeffler HP
Br J Haematol; 2013 Jun; 161(6):811-20. PubMed ID: 23590807
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
[TBL] [Abstract][Full Text] [Related]
15. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells.
Naramura M; Nandwani N; Gu H; Band V; Band H
Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16274-9. PubMed ID: 20805496
[TBL] [Abstract][Full Text] [Related]
16. Expression of the adaptor protein Lnk in leukemia cells.
Gery S; Gueller S; Nowak V; Sohn J; Hofmann WK; Koeffler HP
Exp Hematol; 2009 May; 37(5):585-592.e2. PubMed ID: 19375649
[TBL] [Abstract][Full Text] [Related]
17. CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
Belizaire R; Koochaki SHJ; Udeshi ND; Vedder A; Sun L; Svinkina T; Hartigan C; McConkey M; Kovalcik V; Bizuayehu A; Stanclift C; Schenone M; Carr SA; Padron E; Ebert BL
Blood; 2021 Apr; 137(16):2209-2220. PubMed ID: 33512474
[TBL] [Abstract][Full Text] [Related]
18. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
[TBL] [Abstract][Full Text] [Related]
19. A novel CBL-Bflox/flox mouse model allows tissue-selective fully conditional CBL/CBL-B double-knockout: CD4-Cre mediated CBL/CBL-B deletion occurs in both T-cells and hematopoietic stem cells.
Goetz B; An W; Mohapatra B; Zutshi N; Iseka F; Storck MD; Meza J; Sheinin Y; Band V; Band H
Oncotarget; 2016 Aug; 7(32):51107-51123. PubMed ID: 27276677
[TBL] [Abstract][Full Text] [Related]
20. c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor.
Zuo W; Huang F; Chiang YJ; Li M; Du J; Ding Y; Zhang T; Lee HW; Jeong LS; Chen Y; Deng H; Feng XH; Luo S; Gao C; Chen YG
Mol Cell; 2013 Feb; 49(3):499-510. PubMed ID: 23290524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
